A detailed history of Greenland Capital Management LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Greenland Capital Management LP holds 23,950 shares of PTGX stock, worth $1.12 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
23,950
Holding current value
$1.12 Million
% of portfolio
0.12%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.66 - $34.8 $590,607 - $833,459
23,950 New
23,950 $830 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.3B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Greenland Capital Management LP Portfolio

Follow Greenland Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenland Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Greenland Capital Management LP with notifications on news.